Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals is a biopharmaceutical company with a diversified portfolio of biopharmaceutical product revenue streams and partnerships with leading pharmaceutical and biotechnology companies. The company's revenue consists of royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. Ligand's business model of drug discovery, early-stage development, product reformulation, and partnerships positions it favorably to generate favorable returns for its shareholders. The recent convertible debt offering and the acquisition of XOMA Royalty have strengthened Ligand's balance sheet and support its ability to make future royalty acquisitions. With a diverse portfolio of commercial-stage and late-stage assets, Ligand is well-positioned for long-term growth and generating value for its shareholders. However, risks related to its key royalty revenue contributors, reliance on Captisol revenues, and potential for failed acquisitions or drug development could negatively impact its operations and share value. Our target price of $340 reflects a 10-year DCF valuation framework and supports our Outperform rating.

Ligand Pharmaceuticals is a biopharmaceutical company that operates through a business model focused on drug discovery, early-stage development, and partnerships. However, we believe the company's future growth may be hindered by high demand but low availability of structured capital in the biopharmaceutical market it operates in. Additionally, recent events at a peer drug royalty company have raised concerns about governance standards at similar companies. Furthermore, Ligand's CEO and Board of Directors' involvement in a strategic partnership with a company they have personal ownership in may raise conflict of interest concerns.